Core Viewpoint - Telomir Pharmaceuticals Inc. experienced a significant stock price increase of 38.71% in after-hours trading following the announcement of promising preclinical study results for its lead compound, Telomir-1, which is aimed at reversing DNA methylation in aggressive prostate cancer models [1][2]. Group 1: Study Results - Telomir-1 was reported to reverse abnormal DNA methylation, restoring the function of key tumor suppressor genes MASPIN and RASSF1A, which are often silenced in cancer due to hypermethylation [2][3]. - MASPIN is critical for blocking tumor invasion, regulating cell migration, promoting apoptosis, and enhancing treatment sensitivity. Telomir-1 effectively restored MASPIN activity in vivo by reversing chemotherapy-induced DNA methylation [4]. - RASSF1A is involved in cell cycle control, promoting apoptosis, and suppressing metastasis. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with enhanced effects when combined with chemotherapy [5]. Group 2: Development Status - The company is continuing preclinical development with IND-enabling studies for Telomir-1 [6]. Group 3: Stock Performance - Year-to-date, TELO stock is down 65.53%, but has gained 15.45% over the past month. The stock has traded between $1.12 and $7.08 over the past year, with a market capitalization of $45.84 million and an average daily trading volume of 3.33 million shares [7].